- Home
- HNRG vs IOVA Comparison
HNRG vs IOVA Comparison
Compare HNRG & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- IOVA
- Stock Information
- Founded
- HNRG 1949
- IOVA 2007
- Country
- HNRG United States
- IOVA United States
- Employees
- HNRG N/A
- IOVA N/A
- Industry
- HNRG Coal Mining
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HNRG Energy
- IOVA Health Care
- Exchange
- HNRG Nasdaq
- IOVA Nasdaq
- Market Cap
- HNRG 823.6M
- IOVA 975.1M
- IPO Year
- HNRG N/A
- IOVA N/A
- Fundamental
- Price
- HNRG $19.33
- IOVA $2.25
- Analyst Decision
- HNRG Strong Buy
- IOVA Buy
- Analyst Count
- HNRG 4
- IOVA 11
- Target Price
- HNRG $20.00
- IOVA $10.50
- AVG Volume (30 Days)
- HNRG 549.3K
- IOVA 20.6M
- Earning Date
- HNRG 11-10-2025
- IOVA 11-06-2025
- Dividend Yield
- HNRG N/A
- IOVA N/A
- EPS Growth
- HNRG N/A
- IOVA N/A
- EPS
- HNRG N/A
- IOVA N/A
- Revenue
- HNRG $461,142,000.00
- IOVA $250,425,000.00
- Revenue This Year
- HNRG $11.19
- IOVA $65.15
- Revenue Next Year
- HNRG $4.79
- IOVA $58.47
- P/E Ratio
- HNRG N/A
- IOVA N/A
- Revenue Growth
- HNRG 7.15
- IOVA 175.62
- 52 Week Low
- HNRG $8.37
- IOVA $1.64
- 52 Week High
- HNRG $24.70
- IOVA $9.70
- Technical
- Relative Strength Index (RSI)
- HNRG 43.66
- IOVA 48.72
- Support Level
- HNRG $19.63
- IOVA $2.34
- Resistance Level
- HNRG $21.80
- IOVA $2.62
- Average True Range (ATR)
- HNRG 1.47
- IOVA 0.23
- MACD
- HNRG -0.24
- IOVA -0.01
- Stochastic Oscillator
- HNRG 5.93
- IOVA 47.96
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.